Dendritic cell vaccination and immune monitoring

被引：88

作者：

Aarntzen, E. H. J. G. ^{[1
,2
]}

Figdor, C. G. ^{[2
]}

Adema, G. J. ^{[2
]}

Punt, C. J. A. ^{[1
]}

de Vries, I. J. M. ^{[1
,2
,3
]}

机构：

[1] Radboud Univ Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Med Oncol, Nijmegen, Netherlands

[2] Radboud Univ Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Tumor Immunol, Nijmegen, Netherlands

[3] Radboud Univ Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Pediat Hematooncol, Nijmegen, Netherlands

来源：

CANCER IMMUNOLOGY IMMUNOTHERAPY | 2008年 / 57卷 / 10期

关键词：

dendritic cells; specific immune responses; migration; mRNA transfection; in vivo targeting;

D O I：

10.1007/s00262-008-0553-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We exploited dendritic cells (DC) to vaccinate melanoma patients. We recently demonstrated a statistical significant correlation between favorable clinical outcome and the presence of vaccine-related tumor antigen-specific T cells in delayed type hypersensitivity (DTH) skin biopsies. However, favorable clinical outcome is only observed in a minority of the treated patients. Therefore, it is obvious that current DC-based protocols need to be improved. For this reason, we study in small proof of principle trials the fate, interactions and effectiveness of the injected DC.

引用

页码：1559 / 1568

页数：10

共 69 条

[1] A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells [J].